Descrizione del progetto
Marcatura con deuterio per migliorare la specificità e la sensibilità della risonanza magnetica nella diagnostica del cancro
La tomografia a emissione di positroni (PET) è l’unica tecnologia consolidata per l’imaging molecolare dell’intero corpo, ampiamente utilizzata nella diagnostica del cancro e nella valutazione del trattamento. Tuttavia, la procedura PET è costosa, comporta l’uso di radiazioni ionizzanti e ha una specificità limitata per la captazione di glucosio associata al cancro. Il progetto GLUCO-SCAN, finanziato dal CER, intende sviluppare e valutare un concetto di risonanza magnetica (RM) per tutto il corpo, come l’imaging metabolico al deuterio (DMI), per superare i limiti associati all’attuale PET. L’approccio combinerà un hardware innovativo per la risonanza magnetica, un campionamento dinamico dei dati spettroscopici e algoritmi di apprendimento profondo per creare una nuova generazione di scanner per il corpo intero con la capacità di catturare simultaneamente informazioni morfologiche e molecolari.
Obiettivo
The targeted scientific breakthrough of GLUCO-SCAN is the development and clinical evaluation of a disruptive whole-body molecular imaging concept for cancer assessment. The only currently established whole-body molecular imaging device is positron emission tomography (PET). Glucose (Glc)-sensitive PET is widely used in cancer diagnosis and treatment assessment, but has several major limitations: PET involves harmful ionizing radiation, is expensive, not widely available, and cannot differentiate between cancer-specific and normal cellular glucose uptake. These limitations prohibit an even more widespread use of PET, e.g. for screening. We propose a new Magnetic Resonance Imaging (MRI) concept, whole-body deuterium metabolic imaging (DMI) that will overcome these limitations.
Deuteration is a simple chemical procedure with which it is possible to artificially label a broad range of molecules with an equally broad range of potential applications, e.g. targeting Glc metabolism in cancer. After ingestion, this labeled Glc is metabolized in cells and the label is transferred to all metabolic products, which can be tracked by DMI.
Building on our recent preliminary results in Nature Biomed, we propose a combination of novel MRI hardware, dynamic spectroscopic data sampling, deep learning algorithms, and a clinical validation to answer the following three research questions in a 5-year project:
(i) Is DMI a viable alternative for whole-body cancer assessment?
(ii) How is DMI positioned compared to Glc-sensitive PET?
(iii) Can DMI be performed on widely available MRI systems and simultaneous with standard MRI?
GLUCO-SCAN will fill a gap in current medical imaging by offering an alternative for whole-body PET examinations and potentially even for screening of high risk populations. Ultimately, it will pave the way for a new generation of MR scanners with all-in-one whole-body imaging capability that would capture morphologic and molecular information simultaneously.
Campo scientifico
Parole chiave
Programma(i)
- HORIZON.1.1 - European Research Council (ERC) Main Programme
Argomento(i)
Meccanismo di finanziamento
HORIZON-ERC - HORIZON ERC GrantsIstituzione ospitante
1090 Wien
Austria